The present invention concerns a production bacterial cell for producing lytic phage particles or lytic phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural genes and at least one phage DNA packaging genes, said phage structural gene(s) and phage DNA packaging gene(s) being derived from a lytic bacteriophage, wherein the expression of at least one of said phage structural genes and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by an induction mechanism.

The present invention provides an endoglucanase having excellent heat resistance. Specifically, the present invention provides an endoglucanase satisfying characteristics (A) and (B) below: (A) having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO: 1; and (B) having at least one amino acid substitution selected from the group consisting of K214E, D254E, and S309P.

Disclosed herein are methods and compositions of matter that enable the biological conversion of gaseous waste streams (CO.sub.2, stranded natural gas, flue gas, biogas, landfill gas, etc.) to a platform chemical, 3-hydroxybutyrate, which can in turn be upgraded to fuels and polymers (e.g. polypropylene and polymers). The technology thus presents both a mechanism to valorize gaseous waste streams and establish sustainable production routes to chemicals and plastics via the overexpression of PHB depolymerase while knocking out the AACS pathway in this specific strain of methanotrophic bacteria.

A mannanase at least 75% identical to SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, a poly-nucleotide encoding mannanase, an expression construct comprising the polynucleotide, and a host cell comprising the polynucleotide or the expression construct.

The present invention falls within the technical field of aquaculture, and specifically, the invention relates to a specific solution for preventing and treating bacterial diseases using a Lactococcus lactis lactic acid bacterium transformed to produce an interferon type II (IFN II) immunostimulating cytokine, particularly interferon gamma (IFNg or IFNγ). Said transformed bacterium has been deposited in the Chilean Microbial Genetic Resources Collection at INIA with accession number RGM 2416 dated 22 Oct. 2017. The invention is also related to an immunostimulating food for aquaculture species comprising the lactic acid bacterium transformed with IFN type II from salmonidae. Moreover, the invention relates to the method for preparing said probiotic food, the method for preparing said lactic acid bacterium expressing IFNg, in other words which produces a cytokine that stimulates the antibacterial immune response.

Provided in this disclosure, in some embodiments, are methods and compositions for treating maple syrup urine disease (MSUD) and other conditions characterized by excessive branched-chain amino acids.

The present disclosure relates to a microorganism of the genus Corynebacterium having an increased L-amino acid producing ability, containing NADP-dependent glyceraldehyde-3-phosphate dehydrogenase derived from the genus Lactobacillus. According to the present disclosure, the NADP-dependent glyceraldehyde-3-phosphate dehydrogenase derived from Lactobacillus delbrueckii subsp. bulgaricus is introduced to increase the reducing power through the activity of NADP-dependent glyceraldehyde-3-phosphate dehydrogenase, thereby increasing the L-amino acid producing ability of the strains belonging to the genus Corynebacterium.

Described herein are non-natural variants of prenyltronsfcrases having at least one amino acid substitution as compared to its corresponding natural or unmodified prenyltransferascs. The variants are capable of an increased rate of formation of prenylated aromatic compounds, such as cannabinoids, as compared to a wild type control The prcnyltransferase variants can be expressed in an engineered microbe having a pathway to such cannabinoids, and optionally can include one or more other pathway transgencs to promote formation of substrate(s) for the prcnyltransferases. Therapeutically useful cannabinoids can be purified from engineered cells and cell cultures.

The present application relates to: a novel mutant polypeptide having isopropylmalate synthase activity; and a method for producing L-leucine by using same. L-leucine can be produced at high yield by using the mutant polypeptide according to an embodiment.

The disclosure provides a method for producing an isoprenoid alcohol, isoprenoid alcohol derivative, or a terpene precursor thereof by microbial fermentation. Typically, the method involves culturing a recombinant bacterium in the presence of a gaseous substrate whereby the bacterium produces an isoprenoid alcohol, isoprenoid alcohol derivative, terpene or a precursor thereof. The microorganism may comprise one or more exogenous enzymes.